Clinical Trial

French Prospective Multicentric Study in Real World

Study acronym: OPTIMAL-A
Active, Not Recruiting
View on ClinicalTrials.gov →
Summary
The purpose of this postmarket clinical investigation is to evaluate the levels of glycemic control, quality of life, and satisfaction, as well as the patient experience, and acute diabetes complication rates provided by the Omnipod 5 Automated Insulin Delivery System (referred to as the Omnipod 5 System) in a real-world setting.
Protocol Amendment History 5 changes
notable Primary completion moved earlier: 2027-10 -> 2027-07-30 2026-08-04
minor Completion moved earlier: 2027-10 -> 2027-07-30 2026-08-04
critical Trial status changed: Recruiting → Active, Not Recruiting 2026-07-03
notable Primary completion pushed: 2027-05 -> 2027-10 2026-05-30
minor Completion pushed: 2027-05 -> 2027-10 2026-05-30
Trial Details
NCT Number NCT07039942
Lead Sponsor Insulet Corporation
Conditions Diabetes, Diabetes Mellitus, Type 1 Diabetes
Enrollment 304 participants
Start Date 2025-07-23
Primary Completion 2027-07-30 (estimated)
Study Completion 2027-07-30 (estimated)
Updated on ClinicalTrials.gov 2026-08-03